Pacritinib Citrate Patent Expiration

Pacritinib Citrate is Used for treating myelofibrosis by inhibiting Janus Associated Kinase 2 (JAK2). It was first introduced by Cti Biopharma Corp in its drug Vonjo on Feb 28, 2022.


Pacritinib Citrate Patents

Given below is the list of patents protecting Pacritinib Citrate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vonjo US8153632 Oxygen linked pyrimidine derivatives Jan 17, 2029 Cti Biopharma Corp
Vonjo US8980873 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt Mar 25, 2030 Cti Biopharma Corp
Vonjo US9573964 Oxygen linked pyrimidine derivatives May 05, 2028 Cti Biopharma Corp


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pacritinib Citrate's patents.

Given below is the list recent legal activities going on the following patents of Pacritinib Citrate.

Event Date Patent/Publication
Patent litigations
transaction for FDA Determination of Regulatory Review Period 14 Mar, 2024 US9573964
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9573964
Second letter to regulating agency to determine regulatory review period 30 Sep, 2023 US9573964
Letter from FDA or Dept of Agriculture re PTE application 28 Sep, 2023 US9573964
Payment of Maintenance Fee, 8th Year, Large Entity 31 Aug, 2022 US8980873
Initial letter Re: PTE Application to regulating agency 01 Jul, 2022 US9573964
Change in Power of Attorney (May Include Associate POA) 19 Jan, 2022 US9573964
Email Notification 19 Jan, 2022 US9573964
Email Notification 18 Jan, 2022 US8980873
Change in Power of Attorney (May Include Associate POA) 18 Jan, 2022 US8980873



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳